Daratumumab-containing regimens are recommended as treatment options by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)*†‡

NCCN Guidelines® recommendations in newly diagnosed multiple myeloma

NCCN Guidelines preferred regimen for non-transplant candidates

DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1) primary therapy

NCCN Guidelines other recommended regimen for non-transplant candidates

DVMP: daratumumab (D), bortezomib (V), melphalan (M), and prednisone (P)
(Category 1) primary therapy

NCCN Guidelines useful in certain circumstances for transplant candidates

DVTd: daratumumab (D), bortezomib (V), thalidomide (T), and dexamethasone (d) (Category 2A) primary therapy

NCCN Guidelines recommendations in relapsed or refractory multiple myeloma

NCCN Guidelines preferred regimens for early relapses (1-3 prior therapies)

DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1)

DVd: daratumumab (D), bortezomib (V), and dexamethasone (d) (Category 1)

DKd: daratumumab (D), carfilzomib (K), and dexamethasone (d) (Category 1)

After 2 prior therapies including lenalidomide and a PI
DPd: daratumumab (D), pomalidomide (P), and dexamethasone (d)§ (Category 1)

Useful in certain circumstances

After at least 3 prior therapies including a PI and an immunomodulatory agent or are double refractory to a PI and an immunomodulatory agent
Daratumumab (Category 2A)

PI=proteasome inhibitor.

*Daratumumab includes both daratumumab (DARZALEX®) for intravenous infusion and daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection. Daratumumab and hyaluronidase-fihj for subcutaneous injection has different dosing and administration instructions compared to daratumumab for intravenous infusion.

See nccn.org for definitions of NCCN Categories of Preference and NCCN Categories of Evidence and Consensus.

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 9, 2022. To view the most recent and complete version of the guideline, go online to www.nccn.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

§DARZALEX FASPRO® + Pd is FDA-approved in patients who have received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). DARZALEX® + Pd is FDA-approved in patients who have received ≥2 prior lines of therapy including lenalidomide and a PI.

DARZALEX® and DARZALEX FASPRO® studied in wide range of clinical trials for multiple myeloma

Discover clinical data